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ABSTRACT
Kaposi’s sarcoma-associated herpesvirus (KSHV) is an oncogenic virus associated 
with Kaposi’s sarcoma (KS), a malignancy commonly found in AIDS patients. Despite 
intensive studies in the last two decades, the mechanism of KSHV-induced cellular 
transformation and tumorigenesis remains unclear. In this study, we found that the 
expression of SIRT1, a metabolic sensor, was upregulated in a variety of KSHV-
infected cells. In a model of KSHV-induced cellular transformation, SIRT1 knockdown 
with shRNAs or knockout by CRISPR/Cas9 gene editing dramatically suppressed cell 
proliferation and colony formation in soft agar of KSHV-transformed cells by inducing 
cell cycle arrest and contact inhibition. SIRT1 knockdown or knockout induced the 
expression of cyclin-dependent kinase inhibitor 1B (p27Kip1). Consequently, p27 
knockdown rescued the inhibitory effect of SIRT1 knockdown or knockout on cell 
proliferation and colony formation. Furthermore, treatment of KSHV-transformed 
cells with a SIRT1 inhibitor, nicotinamide (NAM), had the same effect as SIRT1 
knockdown and knockout. NAM significantly inhibited cell proliferation in culture 
and colony formation in soft agar, and induced cell cycle arrest. Significantly, NAM 
inhibited the progression of tumors and extended the survival of mice in a KSHV-
induced tumor model. Collectively, these results demonstrate that SIRT1 suppression 
of p27 is required for KSHV-induced tumorigenesis and identify a potential therapeutic 
target for KS.
INTRODUCTION
Infection by Kaposi’s sarcoma-associated 
herpesvirus (KSHV) is required for the development of 
Kaposi sarcoma (KS) and several lymphoproliferative 
malignancies including primary effusion lymphoma 
(PEL) and a subset of multicentric Castleman’s 
disease [1]. KS is a multifocal mesenchymal neoplasm 
characterized by hyperproliferative spindle-shaped tumor 
cells with frequent involvement of visceral organs. In 
Western countries, KS mostly occurs in the context of 
immunosuppression, especially in HIV-positive patients. 
The incidence of KS has stabilized following a decade of 
decline owing to the availability of anti-retroviral therapy. 
However, KS remains as one of the most important 
malignancies causing significant morbidity and mortality 
in some African regions [2]. There is currently no effective 
therapeutic treatment for KS, stressing the need for better 
understanding the development of KS and discovering 
novel therapeutic targets [3].
Most KS tumor cells are latently infected by 
KSHV, implicating that these cells are the driving 
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force of KS. While numerous KSHV latent genes and 
microRNAs (miRNAs) have been shown to regulate cell 
proliferation and survival [4], the mechanism of KSHV-
induced malignant proliferation remains unclear, which 
is in part due to the lack of a relevant model of KSHV-
induced cellular transformation and tumorigenesis. We 
have recently shown that KSHV can efficiently infect 
and transform primary rat embryonic metanephric 
mesenchymal precursor (MM) cells [5]. KSHV-
transformed MM cells (KMM) efficiently induce tumors 
in nude mice with virological and pathological features 
reminiscent of KS [5]. KMM cells are latently-infected 
by KSHV suggesting an essential role of viral latent genes 
in KSHV induced cellular transformation. This robust 
cell model has opened a new avenue for investigating 
the mechanism of KSHV-induced tumorigenesis. Using 
this model, we have shown that KSHV-encoded miRNAs 
and latent gene vFLIP (ORF71) are essential for KSHV-
induced cellular transformation and tumorigenesis by 
regulating cell proliferation, survival and metabolic 
pathways [6, 7] while vCyclin (ORF72) promotes cellular 
transformation and tumorigenesis by overriding cell 
contact inhibition [8]. In addition, KSHV LANA (ORF73) 
promotes tumorigenesis by interacting with BMP-
activated p-Smad1 to upregulate the expression of Id1 
[9]. Despite these works, the cellular genes and pathways 
required for KSHV-induced transformation remain to be 
discovered.
We have previously shown that SIRT1 promotes 
KSHV latency by inhibiting the expression of the key 
activator for viral lytic replication RTA (ORF50) [10, 11]. 
In PEL cells, knockdown or inhibition of SIRT1 induced 
KSHV lytic replication. However, less than 10% of cells 
underwent lytic replication while most cells experienced 
crisis and eventually died, which indicated that SIRT1 
might contribute to cell proliferation and survival in PEL 
cells.
SIRT1 is a multifaceted, highly conserved NAD+-
dependent class III deacetylase involved in a wide variety 
of cellular processes including cancer [12, 13]. SIRT1 is 
a metabolic sensor and protects cells against metabolic, 
oxidative, and genotoxic stresses through deacetylation 
of multiple substrates including p53 [14], Ku70 [15], and 
FOXO [16, 17] proteins. The expression of SIRT1 and its 
deacetylase activity are repressed in normal cells by tumor 
suppressor proteins such as p53 [18], HIC1 [19], and 
DBC1 [20]. Inactivation of these tumor suppressor genes 
or activation of oncogenes such as E2F1 [21], c-Myc [22], 
and STAT5 [23] in pre-cancer and cancer cells enhance 
SIRT1 expression. SIRT1 is consistently upregulated 
in several primary solid tumors and hematopoietic 
malignancies, and promotes cell proliferation, 
angiogenesis, tumorigenesis and drug resistance [12, 13, 
24]. Intriguingly, some other studies have shown that 
SIRT1 may act as a tumor suppressor. SIRT1 transgenic 
mice reduces the incidence of spontaneous carcinomas and 
the susceptibility to carcinogen-induced liver cancer [25] 
while SIRT1(+/-)/p53(+/-) mice have increased incidences 
of tumors in multiple tissues compared to SIRT1(+/+)/
p53(+/-) mice. Treatment with resveratrol, which activates 
SIRT1, reduces tumorigenesis [26]. Together, these studies 
indicate complex, and possibly tissue-dependent roles of 
SIRT1 in both tumor promotion and suppression.
In this study, we have investigated the role of 
SIRT1 in KSHV-induced cellular transformation and 
tumorigenesis using the KMM model. We have found 
that KSHV infection upregulates the expression of SIRT1. 
We have further shown that SIRT1 is essential for KSHV-
induced cellular transformation, and an inhibitor of 
SIRT1, nicotinamide (NAM), inhibits tumor progression 
and extends the survival of mice in a xenograft model 
of KSHV-induced tumorigenesis. These results identify 
SIRT1 as a putative oncogene and a potential therapeutic 
target of KSHV-associated tumors.
RESULTS
SIRT1 is upregulated in KSHV-infected cells
SIRT1 is upregulated in several types of human 
cancer [12, 13, 24]. We examined the expression of SIRT1 
in a number of cell types latently infected by KSHV. 
SIRT1 was upregulated at both protein and mRNA levels 
in MM cells, telomerase-immortalized human umbilical 
vein endothelial cells (TIVE), telomerase-immortalized 
human dermal microvascular endothelial cells (TIME), 
primary human blood outgrowth endothelial cells (BOEC) 
following KSHV infection (Figure 1A and 1B). KSHV-
infected MM (KMM) and TIVE cells (TIVEK) are 
transformed while KSHV-infected TIME (TIMEK) and 
BOEC cells (BOECK) are not [5, 27–30]. Interestingly, 
the level of SIRT1 upregulation is higher in transformed 
cells than in non-transformed cells (3-fold vs < 2-fold). 
In addition, MM cells are primary cells and KSHV 
infection can cause immediate cellular transformation 
upon establishment of latency and expression of viral 
genes without going though any genetic alterations [5]. 
In contrast, TIVE cells were immortalized by telomerase. 
KSHV infection of TIVE cells did not lead to instant 
cellular transformation [28]. While TIVEK cells are 
transformed, they were selected from a single cell clone 
following long-term culture, which could contain genetic 
changes. In the remaining experiments, we used MM and 
KMM cells to examine SIRT1’s role in KSHV-induced 
cellular transformation.
Knockdown or knockout of SIRT1 suppresses 
cell proliferation and colony formation in soft 
agar of KSHV-transformed cells
To examine the role of SIRT1 in KSHV-induced 
cellular transformation, we performed knockdown of SIRT1 
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in MM and KMM cells with shRNAs targeting two different 
SIRT1 coding sequences (Figure 2A). As previously 
reported, KMM cells proliferated at a significantly faster 
rate than MM cells did [5]. SIRT1 knockdown dramatically 
inhibited cell proliferation of KMM cells while the effect 
on MM cells were marginal (Figure 2B). Both KMM and 
MM cells had similar proliferation rates following SIRT1 
knockdown. Moreover, SIRT1 knockdown significantly 
inhibited the efficiency of colony formation of KMM cells 
in soft agar (Figure 2C and 2D). MM cells failed to form 
any colonies in soft agar with or without SIRT1 knockdown 
as they were not transformed [5]. To further confirm these 
results, we performed SIRT1 knockout using the CRIPSR/
Cas9 system in both MM and KMM cells (Figure 2E). 
As expected, SIRT1 knockout dramatically inhibited cell 
proliferation in KMM cells while there was minimal effect 
on MM cells (Figure 2F). Moreover, SIRT1 knockout 
significantly decreased the efficiency of colony formation of 
KMM cells in soft agar (Figure 2G and 2H). Together, these 
results indicated that SIRT1 was required for optimal cell 
proliferation and colony formation in soft agar of KSHV-
transformed cells.
Our previous study showed that SIRT1 knockdown 
caused a fraction of PEL cells (<10%) to undergo lytic 
replication [10]. We examined the viral lytic replication 
program in KMM cells following SIRT1 knockout. We did 
not detect expression of viral lytic proteins in any KMM 
cells following SIRT1 knockout (Supplementary Figure S1). 
These results are consistent with the fact that KMM cells 
are under tight viral latency [5]. Thus, the effects of SIRT1 
knockdown or knockout on cell proliferation and colony 
formation in soft agar of KSHV-transformed cells were 
unlikely due to the reactivation of viral lytic replication.
Knockdown and knockout of SIRT1 induces cell 
cycle arrest in KSHV-transformed cells
Because knockdown and knockout of SIRT1 
suppressed cell proliferation and colony formation in 
soft agar of KSHV-transformed cells, we examined 
the effects on cell cycle and apoptosis. Cells were 
transduced with SIRT1 shRNA lentiviruses, split at day 
2 post-transduction, pulsed with 10 μM BrdU for 2 h 
at day 4 post-transduction, and examined for cell cycle 
progression. SIRT1 knockdown induced cell cycle arrest 
of KMM cells at G1 phase by increasing G1 phase cells 
from 58% to 75-78%, and decreasing S phase cells 
from 35% to 16-18% (Figure 3A). The effect of SIRT1 
knockdown on cell cycle progression of MM cells were 
more subtle, increasing G1 phase cells from 65% to 71-
75%, and decreasing S phase cells from 28% to 19-21% 
(Figure 3A). In contrast, the effects of SIRT1 knockdown 
on apoptosis were marginal in both MM and KMM cells. 
SIRT1 knockdown only increased the number of apoptotic 
Figure 1: Upregulation of SIRT1 expression in different types of cells latently infected by KSHV. A. Western-blotting 
analysis of SIRT1 protein expression. B. RT-qPCR analysis of SIRT1 mRNA expression. β-actin was used as an internal control. The 
numbers at the bottom of the panel are SIRT1 fold changes (A). The levels of uninfected cells are set as “1” for both protein and mRNA. 
Statistical analysis *p<0.05; **p<0.01; ***p<0.001.
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cells from 2% to 4-5% in KMM cells (Figure 3B). One 
shRNA increased the number of apoptotic cells from 10% 
to 12% while the second one decreased it from 10% to 8% 
in MM cells (Figure 3B). Similar results were obtained 
following SIRT1 knockout. SIRT1 knockout increased G1 
phase cells from 60% to 70% and decreased S phase cells 
from 34% to 23% in KMM cells, while it increased G1 
phase cells from 68% to 74% and decreased S phase cells 
from 25% to 21% in MM cells (Figure 3C). The effect of 
SIRT1 knockout on apoptosis of both MM and KMM cells 
were also subtle by increasing the number of apoptotic 
cells from 2.5% to 3.6% in MM cells and from 0.8% to 
1.5% in KMM cells (Figure 3D). Thus, SIRT1 knockdown 
or knockout mainly affected the cell cycle progression of 
MM and KMM cells rather than apoptosis, and the effect 
on KMM cells was stronger than on MM cells.
Figure 2: SIRT1 knockdown or knockout suppresses cell proliferation and colony formation in soft agar of KSHV-
transformed cells. A. MM and KMM cells were infected with lentiviruses harboring 2 different SIRT1 shRNAs (sh1 and sh2) or a 
scrambled control (Ctl), lysed at day 3 post-infection, and examined for knockdown efficiency by Western-blotting using β-actin as a 
loading control. B. MM and KMM cells with SIRT1 knockdown were counted at different time points after seeding. C. SIRT1 knockdown 
KMM cells at 2×104 were suspended in 1 ml of 0.3% top agar and plated onto one well of 0.5% base agar in 6 well-plate at day 2 post-
infection and maintained for about 3 weeks. Representative pictures of colonies were shown. D. The numbers of colonies from 9 random 
fields described in (C) were counted and the average colony number per field was shown as mean±s.d. E. Western-blotting analysis of 
SIRT1 in the wild-type (WT) and SIRT1 knockout (KO) cultures of MM and KMM cells using β-actin as a loading control. F. Wild-type and 
SIRT1 knockout MM and KMM cells were counted at different days post-seeding. G. Soft agar analysis of wild-type and SIRT1 knockout 
KMM cells. Representative pictures of colonies were shown. H. Colonies from 9 random fields described in (G) were counted and the 
average colony number per field was shown as mean±s.d. Statistical analysis ***p<0.001, NS, not significant.
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SIRT1 knockout induces contact inhibition and 
cyclin-dependent kinase inhibitor 1B (p27Kip1) 
expression
The inhibitory effect of SIRT1 knockdown or knockout 
on cell proliferation only became obvious after day 2 post-
seeding in KMM cells (Figure 2B and 2F). Furthermore, 
SIRT1 knockdown or knockout reduced the efficiency of 
colony formation in soft agar (Figure 2C and 2G). Therefore, 
we further examined the role of SIRT1 in contact inhibition. 
As previously reported, MM cells were contact inhibited 
while KMM cells were not (Figure 4A) [5]. SIRT1 knockout 
rendered KMM cells contact inhibited (Figure 4A), indicating 
that SIRT1 mediated contact inhibition in KMM cells.
Contact inhibition increases the expression of cyclin-
dependent kinase inhibitor 1B (p27Kip1), which binds to 
cyclin-CDK (cyclin-dependent kinase) complexes to induce 
cell proliferation arrest in G1 cell cycle phase [31]. Indeed, 
the p27 protein level was increased in MM cells when the 
cells became confluent (Figure 4B). In this experiment, 
the culture was seeded at 30% confluency, which reached 
50%, 80% and 100% confluency at day 1, 2, and 3 post 
seeding, respectively. Induction of p27 was also observed 
in wild-type KMM cells but at a lower level (Figure 4B). 
Importantly, SIRT1 knockdown increased p27 level in 
KMM cells to level similar to that in MM cells (Figure 4C). 
Similarly, SIRT1 knockout increased p27 level in KMM 
cells (Figure 4D). Thus, while contact inhibition induced 
p27 protein expression in MM cells, upregulation of SIRT1 
in KMM cells inhibited the induction of p27. As a result, 
SIRT1 knockdown in KMM cells induced cell proliferation 
arrest and contact inhibition, and inhibited the efficiency of 
colony formation in soft agar.
p27 knockdown rescues the inhibitory effects 
of SIRT1 knockdown and knockout on cell 
proliferation and colony formation in soft agar
To determine the role of p27 up-regulation in the 
inhibitory effects of SIRT1 knockdown and knockout on 
cell proliferation and colony formation, we performed p27 
knockdown. We first established stable p27 knockdown 
KMM cells expressing 2 different p27 shRNAs or a 
scrambled control shRNA (Figure 5A). We then infected 
stable cells with lentiviruses harboring SIRT1-specific 
shRNAs or a scrambled control. At day 2 post-infection, 
Figure 3: SIRT1 knockdown or knockout induces cell cycle arrest but has minimal effect on apoptosis in KSHV-
transformed cells. A. MM and KMM cells with SIRT1 knockdown as described in Figure 2 were pulsed with 10 μM BrdU for 2 h, 
stained with a pacific blue-conjugated anti-BrdU antibody and propidium iodide, and analyzed by FACS for cell cycle progression. B. MM 
and KMM cells with SIRT1 knockdown were stained with an anti-Annexin V antibody and analyzed by FACS for Annexin V-positive 
cells. C. Cell cycle analysis of wild-type and SIRT1 knockout cultures of MM and KMM cells as described in (A). D. Analysis of Annexin 
V-positive cells in wild-type and SIRT1 knockout cultures of MM and KMM cells as described in (B). Statistical analysis *p<0.05; 
**p<0.01; ***p<0.001, NS, not significant.
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we observed efficient knockdown of SIRT1 (Figure 5A). 
As expected, SIRT1 knockdown inhibited cell proliferation 
by 50-60% in cells stably expressing the p27 scrambled 
control shRNA (Figure 5B). However, cells with 
simultaneous knockdown of SIRT1 and p27 regained the 
proliferation rate. Interestingly, among SIRT1 scrambled 
control shRNA transduced cells, stable knockdown of 
p27 also had higher proliferation rates than their stable 
p27 control knockdown cells, suggesting suboptimal 
suppression of p27 by SIRT1 in KMM cells (Figure 
5B). The results of colony formation in soft agar were 
consistent with those of cell proliferation (Figure 5C and 
5D). SIRT1 knockdown inhibited the efficiency of colony 
formation in cells stably expressing the p27 scrambled 
control shRNA; however, cells with simultaneous 
knockdown of SIRT1 and p27 regained the efficiency 
of colony formation (Figure 5C and 5D). Again, among 
SIRT1 control shRNA scrambled transduced cells, stable 
knockdown of p27 had more robust colony formation 
efficiencies than their stable p27 control knockdown cells 
(Figure 5C and 5D).
To further confirm the role of p27 up-regulation 
in the inhibitory effects of SIRT1 knockdown on cell 
proliferation and colony formation, we transduced the 
SIRT1 knockout cells with p27 shRNAs or the scrambled 
control. We examined the expression levels of SIRT1 
and the efficiencies of p27 knockdown at day 2 post-
transduction (Figure 5E). As expected, knockdown 
of p27 significantly reduced the inhibitory effect of 
SIRT1 knockout on cell proliferation (Figure 5F) and 
the efficiency of colony formation in soft agar (Figure 
5G and 5H). Again, p27 knockdown also increased cell 
proliferation and the efficiency of colony formation in 
KMM cells (Figure 5F-5H). Interestingly, the protein 
expression of SIRT1 was upregulated in the stable p27 
knockdown cells (Figure 5A), which was confirmed in 
transient knockdown KMM cells with one p27 shRNA 
(Figure 5E). However, further experiments are required to 
confirm these results. Taken together, the results indicated 
that p27 upregulation mediated the inhibitory effects of 
SIRT1 knockdown or knockout on cell proliferation and 
colony formation in soft agar.
Figure 4: SIRT1 knockout induces contact inhibition and p27 expression. A. Wild-type (WT) and SIRT1 knockout (KO) 
MM and KMM cells were seeded at the same cell numbers at about 50% confluency and cultured for 10 days with daily change of media. 
At day 10, representative pictures were taken and shown. Contact inhibition was observed in MM cells with or without SIRT1 knockout. 
KMM cells lost contact inhibition as shown by the overlapping cells in culture. SIRT1 knockout induced contact inhibition in KMM cells. 
B. MM and KMM cells were seeded at 30% confluency and lysed at day 1, 2, 3 and 4 post-seeding. The cultures reached 50%, 80%, 100% 
confluency at day 1, 2, 3 post-seeding. The expression levels of SIRT1 and p27 proteins were examined using β-actin as a loading control. 
C. MM and KMM cells were infected with lentiviruses of 2 different SIRT1 shRNAs (sh1 and sh2) or a scrambled control (Ctl), lysed at 
day 3 post-infection, and examined for the expression of SIRT1 and p27 proteins by Western-blotting using β-actin as a loading control. 
D. Wild-type and SIRT1 knockout KMM cells were seeded at 30% confluency and lysed at day 1, 2, 3 and 4 post-seeding. The cultures 
reached 50%, 80%, 100% confluency at day 1, 2, 3 post-seeding. The expression levels of SIRT1 and p27 proteins were examined using 
β-actin as a loading control.
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Figure 5: p27 knockdown rescues the inhibitory effects of SIRT1 inhibition on cell proliferation and colony formation 
of KSHV-transformed cells. A. KMM cells were infected with lentiviruses harboring 2 different p27 shRNAs (sh1 and sh2) or a 
scrambled control (Ctl), and selected with blasticidin for 1 week. The stable p27 knockdown cells were further infected with lentiviruses 
harboring 2 different SIRT1 shRNAs (sh1 and sh2) or a scrambled control (Ctl), lysed at day 3 post-infection, and examined for SIRT1 and 
p27 knockdown efficiencies by Western-blotting using β-actin as a loading control. B. KMM cells with SIRT1 and p27 knockdown were 
counted at day 2 post-infection. C. KMM cells at 2×104 with SIRT1 and p27 knockdown at day 2 post-infection with the SIRT shRNA 
lentiviruses as described in (A) were suspended in 1 ml of 0.3% top agar and plated onto one well of 0.5% base agar in 6 well-plate and 
maintained for about 3 weeks. Representative pictures of colonies were shown. D. The numbers of colonies from 9 random fields described 
in (C) were counted and the average colony number per field was shown as mean±s.d. E. Wild-type (WT) and SIRT1 knockout (KO) KMM 
cells were infected with lentiviruses harboring 2 different p27 shRNAs (sh1 and sh2) or a scrambled control (Ctl), lysed at day 3 post-
infection and examined for the expression of SIRT1 and p27 proteins by Western-blotting using β-actin as a loading control. F. Wild-type 
and SIRT1 knockout KMM cells with and without p27 knockdown were counted at day 2 post-infection. G. Soft agar analysis of wild-type 
and SIRT1 knockout KMM cells with and without p27 knockdown. Representative pictures of colonies were shown. H. Colonies from 9 
random fields described in (G) were counted and the average colony number per field was shown as mean±s.d. Statistical analysis *p<0.05; 
**p<0.01; ***p<0.001, NS, not significant.
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Pharmaceutical inhibition of SIRT1 inhibits cell 
proliferation, colony formation in soft agar and 
tumor formation in vivo of KSHV-transformed 
cells
Both knockdown and knockout of SIRT1 suppressed 
cell proliferation and colony formation in soft agar 
of KSHV-transformed cells, indicating SIRT1 could 
be a putative therapeutic target for KSHV-induced 
tumorigenesis. We examined the effect of NAM, a general 
inhibitor of sirtuins [32], on KSHV-transformed cells. 
Treatment with NAM inhibited cell proliferation of KMM 
cells in a dose-dependent and time-dependent manner 
(Figure 6A). NAM also inhibited the proliferation of MM 
cells but with less effect, particularly at lower doses. At 
10 mM, NAM inhibited the proliferation of KMM cells 
by 65% and MM cells by 35% at day 3 post-treatment. 
NAM also dramatically inhibited the efficiency of colony 
formation of KMM cells in soft agar (Figure 6B and 6C). 
NAM induced cell cycle arrest in both MM and KMM 
cells. Treatment with NAM at 20 mM increased G1 phase 
cells from 59% to 73% and decreased S1 phase cells from 
28% to 14% in MM cells while it increased G1 phase cells 
from 51% to 74% and decreased S1 phase cells from 33% 
to 17% in KMM cells (Figure 6D). NAM also induced low 
levels of apoptosis in both MM and KMM cells. NAM at 
10 and 20 mM increased the number of apoptotic cells 
from 5% to 8.6% and 9.2%, respectively, in MM cells, and 
from 6.1% to 13.1% and 16.8%, respectively, in KMM 
cells (Figure 6E). The effect of NAM on apoptosis on both 
MM and KMM cells were stronger than those observed 
following SIRT1 knockdown or knockout, which might 
be due to its off-target effect.
Having observed the inhibitory effect of NAM 
on KSHV-transformed cells, we further examined 
NAM’s effect on KSHV-induced tumorigenesis. We 
subcutaneously injected 107 KMM cells into each flank 
of 4-week old athymic homozygous nude mice and 
monitored the tumor volume growth. Tumors were 
observed by week 5-6 post-inoculation (Figure 6F). We 
treated the mice with NAM by intraperitoneal injection 
at 300 mg/kg daily at week 11 post-inoculation when the 
average tumor size reached 0.4 cm3. NAM inhibited the 
growth of tumors (Figure 6F) and significantly increased 
the survival of the mice (Figure 6G, P = 0.0431).
DISCUSSION
In this study, we showed that SIRT1 was upregulated 
at both mRNA and protein levels in several cell types latently 
infected by KSHV. In KSHV-transformed cells, SIRT1 was 
required for cell proliferation and cellular transformation 
as knockdown or knockout of SIRT1 induced cell cycle 
arrest and inhibited colony formation in soft agar. We also 
showed that a general inhibitor of sirtuins, NAM, inhibited 
the proliferation and cellular transformation of KSHV-
transformed cells. In vivo, NAM inhibited the progression of 
KSHV-induced tumors, and extended the survival of mice in a 
KS-like model. Together, these results have identified SIRT1 
as a putative oncogene and a potential therapeutic target 
of KSHV-induced tumors. We have previously shown that 
SIRT1 inhibits KSHV lytic replication and the expression of 
viral lytic genes including RTA by epigenetic remodeling of 
viral chromatin, and direct inhibition of RTA transactivation 
of other viral lytic genes [10, 11]. Thus, SIRT1 contributes 
to KSHV-induced cellular transformation and tumorigenesis 
by performing dual functions, i.e. by promoting viral latency, 
and by enhancing cell proliferation and overriding contact 
inhibition (Figure 7).
Despite SIRT1’s oncogenic property in KMM 
cells, overexpression of SIRT1 alone in MM cells was 
insufficient to affect cell proliferation and induce loss 
of contact inhibition (data not shown), indicating that 
dysregulation of other cellular genes and pathways by 
KSHV oncogenes is also required for inducing cellular 
transformation of MM cells.
Mechanistically, we showed that SIRT1 suppressed 
the expression of p27 to promote cell proliferation and 
overcome contact inhibition as SIRT1 knockdown or 
knockout upregulated the expression of p27 protein, 
and induced cell cycle arrest and contact inhibition. 
Furthermore, knockdown of p27 was sufficient to rescue 
the inhibitory effect of SIRT1 knockdown and knockout. 
As SIRT1 is a metabolic sensor, our results provide further 
evidence that KSHV reprograms the metabolic pathways 
to promote cell proliferation and cellular transformation, 
in this case, by upregulating SIRT1 to inhibit p27 [7].
p27 is a member of a family of CKIs and plays 
an important role in fundamental cellular processes and 
human malignancies [33]. p27 inhibits cell proliferation 
and induces contact inhibition; hence it is frequently 
inactivated in human cancers through accelerated 
proteolysis [34]. Downregulation of p27 is associated 
with poor prognosis in a variety of human malignancies, 
whereas restoration of p27 level inhibits tumor growth 
and progression [33, 34]. Because of the importance 
of dysregulating p27 in cancers, identification of new 
mechanisms that regulate its expression and function 
could lead to better understanding of the molecular basis 
of tumorigenesis and developing novel cancer therapies.
Although it has been shown that p27 expression is 
primarily regulated at the post-transcriptional level [35], 
the upstream regulators of p27 remain largely unknown. 
Thus, our results have identified SIRT1 as a novel 
upstream regulator of p27, hence it could be a putative 
therapeutic target. Indeed, a number of studies have 
shown that SIRT1 is a putative oncogene and targeting 
SIRT1 is effective in inhibiting tumor growth and 
progression of liver cancer and chronic myeloid leukemia 
among others [13, 36, 37]. Our results have also shown 
that pharmaceutical inhibition of SIRT1 is an effective 
approach in inhibiting KSHV-induced tumorigenesis.
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In a previous study, we have shown that KSHV 
vCyclin inactivates p27 by inducing its cytoplasmic 
relocalization at contact-inhibited high-density condition 
to promote KSHV-induced cellular transformation 
[8]. Results from the current study showed that SIRT1 
regulated p27 at the post-transcriptional level but not 
transcriptional level. However, we did not observe any 
changes of p27 cytoplasmic relocalization following 
SIRT1 knockdown or knockout (data not shown), 
indicating that SIRT1 might regulate p27 level through the 
Figure 6: SIRT1 inhibitor NAM suppresses cell proliferation and colony formation in vitro, and extends the survival 
of mice in vivo. A. MM and KMM cells were treated with different concentrations of NAM, and the numbers of cells were counted at 
different time points as indicated. B. KMM cells at 2×104 were seeded in the soft agar with different concentrations of NAM and cultured 
in medium with the same concentrations of NAM in the soft agar for 3 weeks. Representative pictures of colonies were shown. C. The 
numbers of colonies from 9 random fields described in (B) were counted and the average colony number per field was shown as mean±s.d. 
D. MM and KMM cells treated with 20 mM NAM for 48 h were collected for cell cycle analysis. E. MM and KMM cells treated with 10 
mM and 20 mM of NAM for 72 h were collected for apoptosis analysis. F. KMM cells at 107 were subcutaneously injected into each flank 
of mice. Tumor volumes were monitored twice a week. When the average tumor sizes reached 0.4 cm3, half of the mice were treated daily 
with NAM at 300 mg/kg while the other half were treated with PBS by IP injection. Tumor volumes, calculated as length×width×height, 
were shown with the dash lines representing the volumes of individual tumors while the solid line representing the average tumor volumes. 
G. Kaplan-Meier survival analysis of mice treated with NAM or vehicle control PBS. Statistical analysis *p<0.05; **p<0.01; ***p<0.001.
Oncotarget75707www.impactjournals.com/oncotarget
nuclear degradation pathway. SIRT1 regulates numerous 
cellular processes by deacetylating transcriptional factors 
and their co-activators such as p53 [36], RelA/p65 [38], 
FOXO [17], and p300 [39]. Thus, SIRT1 could directly 
or indirectly regulate p27 through these transcriptional 
factors and co-activators. Furthermore, other factors, 
such as SKP2 and CKS1, regulate the ubiquitination and 
proteasome degradation of p27 [40–42]; hence SIRT1 
could also directly or indirectly regulate p27 stability 
through these factors.
A recent study has shown that p27-mediated 
contact inhibition deactivates the mammalian target of 
rapamycin (mTOR) pathway, resulting in the suppression 
of the senescence program [43]. KSHV infection induces 
mesenchymal transition and loss of contact inhibition 
[5, 44, 45], which might contribute to the constitutive 
activation of the mTOR pathway in KSHV-infected 
cells [46], and hence the susceptibility of KS tumors to 
rapamycin [47]. vCyclin induces loss of contact inhibition 
at high cell density [8], which might contribute to its 
ability to induce senescence [48] and activation of the 
mTOR pathway [46]. Similarly, SIRT1 mediates KSHV 
inhibition of p27 and contact inhibition could also 
contribute to the activation of the mTOR pathway and 
induction of senescence. Interestingly, vCyclin induction 
of senescence is blocked by vFLIP, which is required for 
the proliferation of KSHV-infected cells [48]. Whether 
vFLIP is required to block SIRT1-mediated senescence 
in KSHV-transformed cells remains to be further 
investigated.
Our results have shown that SIRT1 is upregulated in 
a number of cell types latently infected by KSHV. During 
viral latent infection, only a handful of KSHV latent genes 
are expressed. These include LANA, vFLIP, vCyclin and a 
cluster of miRNAs. Further studies are required to identify 
the viral genes and cellular pathways that mediate KSHV-
induced upregulation of SIRT1.
In this study, NAM dramatically inhibited cell 
proliferation and colony formation in soft agar. In a KSHV-
induced KS-like tumor model, NAM inhibited tumor 
progression and significantly increased the survival of mice. 
NAM, the amide of vitamin B3, also known as nicotinic 
acid or niacin, is the product of sirtuins co-substrate NAD, 
which is a feedback inhibitor of sirtuins’ activity [49]. 
NAM has very low toxicity in vitro and in vivo compared 
to other small molecule inhibitors. However, NAM inhibits 
all seven members of sirtuins (SIRT1-7) [49]. NAM is also 
a co-substrate of poly (ADP-ribose) polymerases (PARPs), 
hence manifests some other effects in addition to inhibition 
of sirtuins [50]. Furthermore, NAM is rapidly metabolized 
in vivo, presenting a challenge for maintaining an effective 
dose for inhibiting SIRT1’s function in vivo [49]. It would 
be interesting to examine the effects of other more potent 
SIRT1 inhibitors in the KSHV-induced tumor model and 
explore their therapeutic potentials for KSHV-induced 
malignancies.
Figure 7: A model illustrating SIRT1 promotion of cellular transformation through two independent mechanisms. 
(1) SIRT1 abolishes cell contact inhibition by suppressing p27 expression; and (2) SIRT1 inhibits RTA expression to promote viral latency 
by increasing H3K27me3 repressive mark and decreasing H3K4me3 active mark on the RTA promoter [10, 11].
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MATERIALS AND METHODS
Cell culture and reagents
MM and KMM cells, BOEC and BOECK cells, 
TIVE and TIVEK (also known as TIVE-LTC) cells, 
and TIME and TIMEK cells were obtained or cultured 
as previously described [5, 27–30]. 293T cells were 
maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) with 10% fetal bovine serum (FBS, Thermo 
Fisher Scientific, Waltham, MA) and antibiotics (100 μg/
mL penicillin and 100 μg/mL streptomycin). NAM was 
purchased from Sigma (Cat.# N0636, St. Louis, MO).
Lentiviral shRNA knockdown
The SIRT1 shRNA constructs were prepared 
as previously described [27]. Briefly, sequences 
of SIRT1 shRNAs were inserted into the pLKO.1 
lentiviral vector. The target sequences included 
shRNA1: GCACCGATCCTCGAACAATTC; shRNA2: 
GCAGGTTGCAGGAATCCAAAG; and scrambled 
shRNA: TTGTACTACACAAAAGTACTG. The p27-
shRNAs constructs were purchased from GenTarget (San 
Diego, CA). The constructs contain a blasticidin selection 
marker and a RFP reporter cassette, which were used for 
selecting infected cells and monitoring infection rate, 
respectively. The sequences of the p27 shRNAs included 
shRNA1: CAAACTCTGAGGACCGGCAT; shRNA2: 
GACCAAATGCCTGACTCGTC; and scrambled shRNA: 
GTCTCCACGCGCAGTACATTT. Supernatants from 
293T cells transfected with the shRNA and packaging 
constructs were collected at 60 h post-transfection 
followed by concentration of the virus at 24,000 rpm 
for 2 h at 4 oC. The virus preparations were used for 
spinning infection of cells at 1,800 rpm for 45 min in the 
presence of 10 μg/ml of polybrene. Cells transduced with 
the lentivirus particles were examined for knockdown 
efficiency at day 3 post-transduction.
CRISPR-Cas9 knockout
MM and KMM cells were first transduced with a 
lentiviral vector pLX-Cas9 expressing HA-tagged Cas9 
and a blastcidin-resistant gene cassette, and selected with 
blastcidin at 10 μg/ml for MM cells and 20 μg/ml for 
KMM cells for 12 days. Stable cell cultures with Cas9 
expression were then transduced with a lentiviral vector 
pLKO-SgRNA expressing a SgRNA and a puromycin-
resistant gene at multiplicity of infection (MOI) 0.3, and 
selected with puromycin at 1 μg/ml for MM cells and 5 
μg/ml for KMM cells for 4 days. Two SgRNAs were 
designed to target the N-terminal of rat SIRT1 SgRNA-1: 
5’-CATGATTGGCACCGATCCTC-3’ and SgRNA-2: 
5’-CGGATAGGTATGCTTTAGGC-3’. A non-targeting 
SgRNA 5’-TGACATCAATTATTATACAT-3’ was used as a 
control. We designed each SgRNA by using Cas-OFFinder 
program (http://www.rgenome.net/cas-offinder/) [51]. 
The resulting cells were counted and diluted to 5 cells per 
ml and seeded onto a 96-well plate with 100 μl per well 
so that approximately 50 cells were seeded into 1 plate. 
Individual cell seeding in most of the wells was confirmed 
by microscopy observation. Only clones from wells 
expanded from one cell were chosen to screen for SIRT1 
expression by Western-blotting using an antibody against 
the C-terminal of rat SIRT1 protein (Cat.# 8469, Cell 
Signaling Technology, Danvers, MA). To further confirm 
the disruption of the gene in the selected clones, genomic 
DNA was extracted and used to amplify a fragment of 661 
bp for SgRNA-1 and a fragment of 863 bp for SgRNA-2, 
respectively, spanning the targeting sites by PCRs. The 
PCR products were then sequenced using internal primers. 
In the cases of multiple sequence peaks, the PCR products 
were cloned into the pCR2.1 vector and approximately 10-
20 bacterial colonies from each cell clone were selected 
for sequencing. Six SIRT1 knockout and 6 non-targeting 
(wild-type SIRT1) KMM clones were selected and pooled 
together, respectively. Similarly, 2 SIRT1 knockout and 2 
non-targeting (wild-type SIRT1) MM clones were selected 
and pooled together, respectively, for further study.
Soft agar assay
Soft agar assay was performed as previously 
described with minor modifications [5]. Briefly, a total of 
2×104 cells suspended in 1 ml of 0.3% top agar (Cat.# 
A5431, Sigma, St. Louis, MO) were plated onto one well 
of 0.5% base agar in 6 well-plates and cultured for 2-3 
weeks. Colonies with a diameter > 50 μm were counted 
and photographed with a microscope.
Cell cycle, BrdU incorporation and apoptosis 
assays
Cell cycle analysis were performed by staining with 
propidium iodide (Cat.# P4864, Sigma, St. Louis, MO). BrdU 
incorporation was performed by pulsing cells with 10 μM 
BrdU (Cat.# B5002, Sigma, St. Louis, MO) for 2 h followed 
by staining with a Pacific Blue conjugated anti-BrdU antibody 
(Cat.# B35129, Thermo Fisher Scientific, Waltham, MA). A 
PE-Cyanine 7 conjugated anti-Annexin V antibody (Cat.# 25-
8103-74, eBioscience, San Diego, CA) was used to detect 
apoptotic cells following the instructions of the manufacturer. 
Flow cytometry was performed in a FACSCanto System (BD 
Biosciences, San Jose, CA). Analysis was performed with 
FlowJo (Treestar, Ashland, OR).
Reverse transcription quantitative real-time 
polymerase-chain reaction (RT-qPCR)
Total RNA was isolated with the TRI Reagent (Cat.# 
T9424, Sigma, St. Louis, MO) according to the instructions 
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of the manufacturer. Reverse transcription was performed 
with total RNA using Maxima H Minus First Strand cDNA 
Synthesis Kit (Cat.# K1652, Thermo Fisher Scientific, 
Waltham, MA). qPCR analysis was performed on Eppendorf 
Real Plexusing KAPA SYBR FAST qPCR Kits (Cat.# 
KK4602, Kapa Biosystems, Wilmington, MA). The relative 
expression levels of target genes were normalized to that of 
the internal control gene β-actin, which yielded 2^-ΔΔCt values. 
The primers rat SIRT1-F: GAGTGTGCTGGAGGATCTGG 
and rat SIRT1-R: AGTGCTCTGATTTGTCTGGTGT 
were used for rat SIRT1; rat β-actin-F: 
CCATGTACCCAGGCATTGCT and rat β-actin-R: 
AGCCACCAATCCACACAGAG were used for rat 
β-actin; human SIRT1-F: GGACATGCCAGAGTCCAAGT 
and human SIRT1-R: CCCAAATCCAGCTCCTCCAG 
were used for human SIRT1; and human β-actin-F: 
ATCATTGCTCCTCCTGAGCG and human β-actin-R: 
CGGACTCGTCATACTCCTGC were used for human 
β-actin.
Western-blotting analysis
Total cell lysates were separated in SDS 
polyacrylamide gels, electrophoretically transferred to 
nitrocellulose membranes (GE Healthcare, Pasadena, CA). 
The membranes were incubated sequentially with primary 
and secondary antibodies. The signal was developed 
using Luminiata Crescendo Western HRP substrate 
(Cat.# WBLUR0500, EMD Millipore, San Diego, CA). 
The antibodies used for Western-blotting included rabbit 
antibodies (mAbs) to SIRT1 (Cat.# 8469) and p27 (Cat.# 
3686) from Cell Signaling Technology (Danvers, MA), and 
β-actin (Cat.# sc8432) from Santa Cruz (Santa Cruz, CA).
Mouse model
The use of animals was approved by the University 
of Southern California Institutional Animal Care and 
Use Committee. Male athymic homozygous nude mice 
(4-weeks-old) were purchased from Harlan (Indianapolis, 
IN). KMM cells (107 cells) were injected subcutaneously 
into each flank of both flanks of a mouse. Tumor volumes 
were monitored twice weekly and calculated according to 
the following formula (length×width×height). We started 
the NAM treatment when the average tumor size reached 
0.4 cm3. Treatment was conducted by intraperitoneal 
injection of NAM at a dose of 300 mg/kg/daily. PBS was 
used as a vehicle control. The mice were terminated by 
CO2 inhalation when one of the tumors reached 1.2 cm3.
Statistical analysis
For survival study, Kaplan-Meier survival analysis 
was performed and statistical significance was calculated 
using the log-rank test. For other data analysis, the 
two-tailed t-test or F-test of equality of variances were 
performed and P < 0.05 was considered statistically 
significant. Statistical symbols “*”, “**” and “***” 
represent P < 0.05, < 0.01 and <0.001, respectively, while 
“NS” indicates “not significant”.
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